The US FDA last week placed clinical holds on the testing of two separate investigational anti-nerve growth factor (NGF) pain drugs under development by Johnson & Johnson and Regeneron Pharmaceuticals and its partner Sanofi-Aventis after a case of avascular necrosis of a joint was confirmed in a clinical trial participant.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?